

# ReNeuron Group Plc

07:51 14 Dec 2017

## ReNeuron receives approval from US authorities to kick off phase IIb stroke trial

ReNeuron Group Plc (LON:RENE) has been given the green light from US authorities to kick off a phase IIb study of its CTX cell therapy candidate for stroke disability.

Long-term data from the PISCES II trial earlier this year showed the treatment has the potential to improve the disability of stroke patients.

READ: ReNeuron boss 'delighted' with long-term stroke data PISCES III - as this next study will be called - will be much bigger, recruiting 110 patients across 25 sites in the US.

It will compare how many patients treated with either the CTX therapy or a placebo demonstrate a "clinically important improvement" on the Modified Rankin Scale - a measure of disability and dependence.

Data from the study is expected towards the end of 2019.

"We are delighted to have received regulatory approval to commence our first clinical trial in the US with our CTX cell therapy candidate for stroke disability," said chief executive Olav Hellebø.

"No therapeutic interventions are currently available to improve motor function and quality of life for disabled stroke patients.

"This important clinical trial represents a further step towards potentially meeting that very significant unmet need and we look forward to initiating the study during the first half of next year."

Progress made in first half

Thursday's approval caps off a productive six months for the cell-based therapeutics specialist, during which it also started dosing patients in the phase II element of the ongoing phase I/II clinical trial of its hRPC stem cell therapy candidate for retinitis pigmentosa.

A phase II trial of hRPC in the degenerative eye disease is due to get underway in the middle of 2018, alongside a phase II study in cone rod dystrophy.

Elsewhere, pre-clinical data of ReNeuron's ExoPr0 exosome therapy candidate also showed it may have a "significant effect" in regulating cell growth and reducing cancer cell proliferation.

The company also thinks it could be used to target "multiple" other diseases but for the time being it will focus on cancer, and an initial clinical trial application is planned for 2019.

Well funded

ReNeuron recorded a loss of £9.6m (2016: loss of £7.7m) for the six months through to September 30

**Price:** 91p

**Market Cap:** £28.8M

### 1 Year Share Price Graph



### Share Information

**Code:** RENE

**Listing:** AIM

**52 week High Low**  
**250p 1.95p**

**Sector:** Pharma & Biotech

**Website:** www.reneuron.com

### Company Synopsis:

ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need. ReNeuron is traded in the NEX Exchange HERE.

**Author:**

**Proactive Investors Ltd**

**+44 (0)207 989 0813**

**action@proactiveinvestors.com**

At the end of the period the AIM-quoted group had £45.3m of cash and cash equivalents (31 March: £53.1m).

"During the period, our therapeutic development programmes have continued to progress to plan," added Hellebø.

"This progress positions us for the delivery of further significant clinical milestones across our therapeutic programmes during each of the next three years."

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.